Target type: biologicalprocess
Any process that stops, prevents, or reduces the frequency, rate, or extent of T cell mediated immunity. [GOC:add]
Negative regulation of T cell mediated immunity is a complex process that involves a variety of mechanisms to prevent excessive or inappropriate T cell activation, ensuring immune homeostasis and preventing autoimmunity. Key players in this process include regulatory T cells (Tregs), inhibitory receptors on T cells, and various cytokines that modulate T cell responses.
**1. Regulatory T Cells (Tregs):**
- Tregs are a specialized subset of T lymphocytes that actively suppress the activation and effector functions of other T cells.
- They express the transcription factor Foxp3, which is essential for their development and function.
- Tregs exert their suppressive activity through various mechanisms, including:
- **Cytokine production:** Tregs secrete immunosuppressive cytokines like IL-10 and TGF-β, which dampen T cell responses.
- **Cell contact-mediated suppression:** Tregs interact directly with target T cells through the expression of surface molecules like CTLA-4 and CD25, leading to their inactivation.
- **Metabolic modulation:** Tregs can influence the metabolic environment of T cells, promoting a less active state.
**2. Inhibitory Receptors on T Cells:**
- T cell receptors (TCRs) are responsible for recognizing and binding to antigens presented on antigen-presenting cells (APCs).
- However, T cells also express a variety of inhibitory receptors that counterbalance TCR activation signals.
- Examples include:
- **CTLA-4:** Binds to the same ligands as CD28 (a positive co-stimulatory receptor), blocking CD28 signaling and inhibiting T cell activation.
- **PD-1:** Binds to PD-L1 and PD-L2 on APCs, leading to T cell exhaustion and suppression.
- **LAG-3:** Interacts with MHC class II molecules on APCs, suppressing T cell activation.
**3. Cytokines:**
- Cytokines, particularly those with immunosuppressive properties, play a crucial role in regulating T cell responses.
- **IL-10:** Secreted by Tregs and other immune cells, inhibits T cell proliferation and cytokine production.
- **TGF-β:** Promotes Tregs differentiation and inhibits T cell activation.
- **IL-35:** A recently discovered cytokine with potent immunosuppressive effects, inducing T cell suppression.
**4. Other Mechanisms:**
- **Apoptosis:** T cells undergo programmed cell death (apoptosis) when they are no longer needed, preventing excessive immune responses.
- **Metabolic reprogramming:** T cell activation is tightly linked to metabolic changes. Negative regulation can involve shifting T cells to a less metabolically active state, reducing their capacity for activation.
- **Immunological tolerance:** The immune system is able to tolerate certain antigens, preventing immune responses against self-antigens, which is crucial for preventing autoimmunity.
**Disruption of Negative Regulation:**
- Failure of these negative regulatory mechanisms can lead to uncontrolled T cell activation, potentially causing autoimmune diseases, allergies, or inflammatory conditions.
- Conversely, excessive negative regulation can lead to immunosuppression and increased susceptibility to infections.
'
"
Protein | Definition | Taxonomy |
---|---|---|
Dual specificity protein phosphatase 22 | A dual specificity protein phosphatase 22 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q9NRW4] | Homo sapiens (human) |
Nucleotide-binding oligomerization domain-containing protein 2 | A nucleotide-binding oligomerization domain-containing protein 2 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q9HC29] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
paclitaxel | Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL). | taxane diterpenoid; tetracyclic diterpenoid | antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent |
docetaxel anhydrous | docetaxel anhydrous : A tetracyclic diterpenoid that is paclitaxel with the N-benzyloxycarbonyl group replaced by N-tert-butoxycarbonyl, and the acetoxy group at position 10 replaced by a hydroxy group. Docetaxel: A semisynthetic analog of PACLITAXEL used in the treatment of locally advanced or metastatic BREAST NEOPLASMS and NON-SMALL CELL LUNG CANCER. | secondary alpha-hydroxy ketone; tetracyclic diterpenoid | antimalarial; antineoplastic agent; photosensitizing agent |
muramyl dipeptide | glycopeptide | immunological adjuvant | |
3-methyl-7-pentyl-8-(2-phenylethylthio)purine-2,6-dione | oxopurine | ||
3-methyl-7-(phenylmethyl)-8-(propan-2-ylthio)purine-2,6-dione | oxopurine | ||
1-(4-methylphenyl)sulfonyl-2-benzimidazolamine | sulfonamide | ||
1-(4-chlorophenyl)sulfonyl-2-benzimidazolamine | sulfonamide | ||
1-(benzenesulfonyl)-2-benzimidazolamine | sulfonamide | ||
1-(4-nitrophenyl)sulfonyl-2-benzimidazolamine | sulfonamide | ||
illudalic acid | illudalic acid: isolated from Clitocybe illudens; structure in first source | ||
pd 166285 | |||
1-(4-methoxyphenyl)sulfonyl-2-benzimidazolamine | sulfonamide | ||
5,6-dimethyl-1-(4-methylphenyl)sulfonyl-2-benzimidazolamine | sulfonamide |